Publication date: Feb 01, 2025
The coronavirus disease 2019 pandemic encouraged rapid vaccine development, with a fast-evolving evidence base pre- and post-implementation. We developed a comprehensive web hub to promote swift information synthesis for present and future threats. By expanding our coronavirus disease 2019 periodically updated living systematic review to Chikungunya, Lassa fever, and Disease X, we will continuously capture data on vaccine safety and effectiveness.
Open Access PDF
| Concepts | Keywords |
|---|---|
| Future | Child |
| Global | COVID-19 |
| Pandemic | COVID-19 Vaccines |
| Systematic | COVID-19 Vaccines |
| Vaccines | Female |
| Humans | |
| Meta-Analysis as Topic | |
| Pregnancy | |
| SARS-CoV-2 | |
| Vaccines | |
| Vaccines |
Semantics
| Type | Source | Name |
|---|---|---|
| drug | DRUGBANK | Huperzine B |
| disease | MESH | Emergency |
| disease | MESH | coronavirus disease 2019 |
| disease | MESH | Lassa fever |
| drug | DRUGBANK | Coenzyme M |
| disease | MESH | emerging infectious diseases |
| disease | IDO | process |
| disease | IDO | pathogen |
| drug | DRUGBANK | Indoleacetic acid |
| disease | MESH | spontaneous abortion |
| disease | MESH | malformations |
| disease | MESH | preterm birth |
| disease | MESH | stillbirth |
| disease | MESH | neonatal death |
| disease | MESH | morbidity |
| disease | MESH | infectious diseases |
| disease | MESH | vaccine preventable diseases |
| disease | MESH | infection |
Original Article
(Visited 1 times, 1 visits today)